FALLS CHURCH, Va., Feb. 16, 2016 -- The following is a statement by Randy Belote, vice president of strategic communications for Northrop Grumman Corporation:
Northrop Grumman is pleased that the U.S. Government Accountability Office (GAO) has denied Boeing's protest and reaffirmed the Air Force's decision to award Northrop Grumman the Long-Range Strike Bomber (LRS-B) contract. This confirms that the U.S. Air Force conducted an extraordinarily thorough selection process and selected the most capable and affordable solution.
The LRS-B is vitally important to national security and we are delighted to be resuming work on the next-generation Long-Range Strike Bomber.
CONTACT: Randy Belote
703-280-3500
[email protected]


Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



